Welcome to our dedicated page for Iterum Therapeutics Plc news (Ticker: ITRM), a resource for investors and traders seeking the latest updates and insights on Iterum Therapeutics Plc stock.
Iterum Therapeutics Plc (ITRM) is a clinical-stage pharmaceutical company pioneering treatments for multi-drug resistant infections. This page provides investors and industry professionals with verified news and press releases about ITRM's advancements in oral and IV anti-infectives.
Access real-time updates on clinical trials, regulatory milestones like Qualified Infectious Disease Product (QIDP) designations, and strategic partnerships. Our curated repository ensures you stay informed about developments in antibiotic resistance solutions without promotional bias.
Key coverage areas include Phase 3 trial results, FDA communications, financial reporting, and R&D collaborations. All content is sourced directly from Iterum Therapeutics and reputable financial publications to ensure accuracy.
Bookmark this page for streamlined access to ITRM's latest progress in addressing global health challenges through differentiated anti-infective therapies.
Dublin, Ireland and Chicago, April 20, 2023 – Iterum Therapeutics (Nasdaq: ITRM) announced the presentation of two posters at the 33rd Annual European Congress of Clinical Microbiology and Infectious Disease (ECCMID) in Copenhagen on April 17, 2023. The presentations focused on a novel analysis method called Desirability of Outcome Ranking (DOOR) applied to Phase 3 trials of their antibiotic sulopenem for uncomplicated (uUTI) and complicated urinary tract infections (cUTI). Key findings demonstrated that oral sulopenem was more effective than ciprofloxacin for uUTI and comparable to ertapenem for cUTI. This approach, though not yet a primary endpoint for regulatory approval, reflects a commitment to evaluating patient outcomes comprehensively. Iterum is advancing sulopenem, an innovative treatment for multi-drug resistant infections, with QIDP and Fast Track designations for multiple indications.
FAQ
What is the current stock price of Iterum Therapeutics Plc (ITRM)?
What is the market cap of Iterum Therapeutics Plc (ITRM)?
